Oventus Medical provided a clinical update, following the completion of its latest pilot study. Oventus has developed a clinical trial program collaborating with some of Australia's leading research organizations to gather evidence evaluating the O2Vent T and its unique patented airway. This follows the completion of the first clinical trial in 2016 which delivered positive results for people with obstructive sleep apnoea (OSA), including those with nasal obstruction, believed to be due to the presence of the airway. The latest pilot study showed that O2Vent T when used as a standalone device, reduces the number of respiratory events from an average AHI of 37 to AHI of 8 (78%), reduces pressure swings at the back of the mouth to similar levels as CPAP, and was effective in the presence of high nasal resistance (nasal obstruction). In addition, when the external airway of O2 Vent T was used as a CPAP interface, pressure requirements were reduced (66%) to 2.3 cmH2O (CPAPs typically operate at 5-20cmH2O) and the appliance provided a stable airway at low pressure without the need for a mask. The design of the CPAP connection enabled simultaneous nasal CPAP delivery, while patients continued to breathe through the device airway. This is beneficial for the large percentage of mouth breathing patients that cannot tolerate CPAP.